New pyrrolidine‐carboxamide derivatives as dual antiproliferative EGFR/CDK2 inhibitors.

MLA

Frejat, Frias Obaid Arhema, et al. “New Pyrrolidine‐carboxamide Derivatives as Dual Antiproliferative EGFR/CDK2 Inhibitors.” Chemical Biology & Drug Design, vol. 103, no. 1, Jan. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1111/cbdd.14422.

APA

Frejat, F. O. A., Zhao, B., Furaijit, N., Wang, L., Abou, Z. H. A., Fathy, H. M., Mohamed, F. A. M., Youssif, B. G. M., & Wu, C. (2024). New pyrrolidine‐carboxamide derivatives as dual antiproliferative EGFR/CDK2 inhibitors. Chemical Biology & Drug Design, 103(1), 1–12. https://doi.org/10.1111/cbdd.14422

Chicago

Frejat, Frias Obaid Arhema, Bingbing Zhao, Nooruldeen Furaijit, Lihong Wang, Zied, Hesham A. Abou, Hazem M. Fathy, Fatma A. M. Mohamed, Bahaa G. M. Youssif, and Chunli Wu. 2024. “New Pyrrolidine‐carboxamide Derivatives as Dual Antiproliferative EGFR/CDK2 Inhibitors.” Chemical Biology & Drug Design 103 (1): 1–12. doi:10.1111/cbdd.14422.